Literature DB >> 18042730

Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.

Gernot Habicht1, Christian Haupt, Ralf P Friedrich, Peter Hortschansky, Carsten Sachse, Jessica Meinhardt, Karin Wieligmann, Gerald P Gellermann, Michael Brodhun, Jürgen Götz, Karl-Jürgen Halbhuber, Christoph Röcken, Uwe Horn, Marcus Fändrich.   

Abstract

The formation of amyloid fibrils is a common biochemical characteristic that occurs in Alzheimer's disease and several other amyloidoses. The unifying structural feature of amyloid fibrils is their specific type of beta-sheet conformation that differentiates these fibrils from the products of normal protein folding reactions. Here we describe the generation of an antibody domain, termed B10, that recognizes an amyloid-specific and conformationally defined epitope. This antibody domain was selected by phage-display from a recombinant library of camelid antibody domains. Surface plasmon resonance, immunoblots, and immunohistochemistry show that this antibody domain distinguishes Abeta amyloid fibrils from disaggregated Abeta peptide as well as from specific Abeta oligomers. The antibody domain possesses functional activity in preventing the formation of mature amyloid fibrils by stabilizing Abeta protofibrils. These data suggest possible applications of B10 in the detection of amyloid fibrils or in the modulation of their formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042730      PMCID: PMC2148273          DOI: 10.1073/pnas.0703793104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Amyloid fibrils from muscle myoglobin.

Authors:  M Fändrich; M A Fletcher; C M Dobson
Journal:  Nature       Date:  2001-03-08       Impact factor: 49.962

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 3.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

4.  Antibody-mediated resolution of light chain-associated amyloid deposits.

Authors:  R Hrncic; J Wall; D A Wolfenbarger; C L Murphy; M Schell; D T Weiss; A Solomon
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

5.  A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme.

Authors:  Mireille Dumoulin; Alexander M Last; Aline Desmyter; Klaas Decanniere; Denis Canet; Göran Larsson; Andrew Spencer; David B Archer; Jurgen Sasse; Serge Muyldermans; Lode Wyns; Christina Redfield; André Matagne; Carol V Robinson; Christopher M Dobson
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

6.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

7.  Conformational Abs recognizing a generic amyloid fibril epitope.

Authors:  Brian O'Nuallain; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

8.  Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

Authors:  Christoph Hock; Uwe Konietzko; Andreas Papassotiropoulos; Axel Wollmer; Johannes Streffer; Ruth C von Rotz; Gabriela Davey; Eva Moritz; Roger M Nitsch
Journal:  Nat Med       Date:  2002-10-15       Impact factor: 53.440

9.  Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies.

Authors:  F L Heppner; C Musahl; I Arrighi; M A Klein; T Rülicke; B Oesch; R M Zinkernagel; U Kalinke; A Aguzzi
Journal:  Science       Date:  2001-09-06       Impact factor: 47.728

10.  Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.

Authors:  Yuesong Gong; Lei Chang; Kirsten L Viola; Pascale N Lacor; Mary P Lambert; Caleb E Finch; Grant A Krafft; William L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

View more
  77 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

2.  Structure-based design of conformation- and sequence-specific antibodies against amyloid β.

Authors:  Joseph M Perchiacca; Ali Reza A Ladiwala; Moumita Bhattacharya; Peter M Tessier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-14       Impact factor: 11.205

Review 3.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

4.  Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils.

Authors:  Jan Bieschke; Martin Herbst; Thomas Wiglenda; Ralf P Friedrich; Annett Boeddrich; Franziska Schiele; Daniela Kleckers; Juan Miguel Lopez del Amo; Björn A Grüning; Qinwen Wang; Michael R Schmidt; Rudi Lurz; Roger Anwyl; Sigrid Schnoegl; Marcus Fändrich; Ronald F Frank; Bernd Reif; Stefan Günther; Dominic M Walsh; Erich E Wanker
Journal:  Nat Chem Biol       Date:  2011-11-20       Impact factor: 15.040

5.  Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity.

Authors:  Ali Reza A Ladiwala; Jeffrey Litt; Ravi S Kane; Darryl S Aucoin; Steven O Smith; Swarnim Ranjan; Judianne Davis; William E Van Nostrand; Peter M Tessier
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

Review 6.  Antibody-enabled small-molecule drug discovery.

Authors:  Alastair D G Lawson
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

7.  Structural determination of Abeta25-35 micelles by molecular dynamics simulations.

Authors:  Xiang Yu; Qiuming Wang; Jie Zheng
Journal:  Biophys J       Date:  2010-07-21       Impact factor: 4.033

8.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

Review 9.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

10.  Differential recognition of vascular and parenchymal beta amyloid deposition.

Authors:  Kim S Rutgers; Alexandra van Remoortere; Mark A van Buchem; C Theo Verrips; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch; Sjoerd G van Duinen; Marion L Maat-Schieman; Silvère M van der Maarel
Journal:  Neurobiol Aging       Date:  2009-12-16       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.